{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T11:49:35Z","timestamp":1764589775956,"version":"3.46.0"},"reference-count":54,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"published-print":{"date-parts":[[2025,11,26]]},"DOI":"10.1080\/14737167.2025.2507427","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T04:59:07Z","timestamp":1747371547000},"page":"1421-1426","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Budget impact of lecanemab for medicare beneficiaries with early Alzheimer\u2019s disease in the United States: a subgroup analysis"],"prefix":"10.1080","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0250-6649","authenticated-orcid":false,"given":"Vassiki","family":"Sanogo","sequence":"first","affiliation":[{"name":"Integrity Analytics","place":["Florida, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reem Dhayan","family":"Saud Almutairi","sequence":"additional","affiliation":[{"name":"Integrity Analytics","place":["Florida, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vakaramoko","family":"Diaby","sequence":"additional","affiliation":[{"name":"University of Florida","place":["Florida, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"e_1_3_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41514-024-00136-6"},{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12638"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13016"},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13809"},{"volume-title":"Lilly\u2019s donanemab receives US FDA\u2019s breakthrough therapy designation for treatment of Alzheimer\u2019s disease","author":"Eli Lilly and Co","key":"e_1_3_8_6_1","unstructured":"Eli Lilly and Co. Lilly\u2019s donanemab receives US FDA\u2019s breakthrough therapy designation for treatment of Alzheimer\u2019s disease. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-donanemab-receives-us-fdas-breakthrough-therapy."},{"key":"e_1_3_8_7_1","unstructured":"Eisai Inc. A placebo-controlled double-blind parallel-group Bayesian adaptive randomization design and dose regimen-finding study with an open-label extension phase to evaluate safety tolerability and efficacy of BAN2401 in subjects with early Alzheimer\u2019s disease. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 Feb 29 [cited 2025 May 20]. Report No.: NCT01767311. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01767311. Last updated 2025 Jan 22."},{"key":"e_1_3_8_8_1","unstructured":"Eisai Inc. A placebo-controlled double-blind parallel-group 18-month study with an open-label extension phase to confirm safety and efficacy of BAN2401 in subjects with early Alzheimer\u2019s disease. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 Feb 29 [cited 2025 May 20]. Report No.: NCT03887455. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03887455. Last updated 2025 Apr 16."},{"key":"e_1_3_8_9_1","article-title":"Beta-amyloid antibodies for early Alzheimer\u2019s disease: effectiveness and value","author":"Lin GA","year":"2023","unstructured":"Lin GA, Whittington MD, Wright A, et al. Beta-amyloid antibodies for early Alzheimer\u2019s disease: effectiveness and value. Evidence Report Inst Clin And Econ Rev. 2023 Apr 17.","journal-title":"Evidence Report Inst Clin And Econ Rev"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00460-1"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100657"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708"},{"key":"e_1_3_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06177-5"},{"key":"e_1_3_8_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.12548"},{"key":"e_1_3_8_16_1","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/171379"},{"key":"e_1_3_8_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2023.1749"},{"key":"e_1_3_8_18_1","unstructured":"The Institute for Clinical and Economic Review (ICER). ICER publishes final evidence report on lecanemab for Alzheimer\u2019s disease."},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.086386"},{"key":"e_1_3_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00187.x"},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.08.2291"},{"key":"e_1_3_8_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-017-0067-7"},{"key":"e_1_3_8_23_1","unstructured":"Medicare Advantage. Medicare advantage & other health plans. Available from: https:\/\/www.medicare.gov\/"},{"key":"e_1_3_8_24_1","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2023.0059"},{"volume-title":"Advanced drug search","author":"IBM Micromedex","key":"e_1_3_8_25_1","unstructured":"IBM Micromedex. Advanced drug search."},{"key":"e_1_3_8_26_1","unstructured":"CMS. Search the Physician Fee Schedule. 2023 [cited 2025 Jan 22]. Available from: https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search"},{"key":"e_1_3_8_27_1","doi-asserted-by":"publisher","DOI":"10.1037\/amp0000904"},{"key":"e_1_3_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12362"},{"key":"e_1_3_8_29_1","article-title":"Alzheimer\u2019s disease mortality rate in the United States from 2000 to 2021","author":"Statista","unstructured":"Statista. Alzheimer\u2019s disease mortality rate in the United States from 2000 to 2021. Statista Res Department.","journal-title":"Statista Res Department"},{"key":"e_1_3_8_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-82593-7"},{"key":"e_1_3_8_31_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-220865"},{"key":"e_1_3_8_32_1","unstructured":"Neilsberg Research. United States population by race & ethnicity. U.S. Census bureau American Community Survey (ACS) 2018\u20132022 5-year estimates."},{"key":"e_1_3_8_33_1","unstructured":"US Census. American community survey (ACS). US Census Bureau."},{"key":"e_1_3_8_34_1","unstructured":"Christian Worstell. Medicare statistics 2024: explore state and national Medicare data in our regularly updated report. Medicare Advantage."},{"key":"e_1_3_8_35_1","unstructured":"FDA Donanemab Label. KISUNLA (donanemab-azbt) injection for intravenous use initial U.S. approval: 2024. 2024."},{"key":"e_1_3_8_36_1","volume-title":"ADLARITY\u00ae (donepezil transdermal system) initial U.S. Approval: 1996","author":"FDA Donepezil Label","year":"2022","unstructured":"FDA Donepezil Label. ADLARITY\u00ae (donepezil transdermal system) initial U.S. Approval: 1996 (U.S. Food and Drug Administration (FDA). 2022."},{"key":"e_1_3_8_37_1","volume-title":"ZUNVEYL (benzgalantamine) delayed-release tablets, for oral use initial U.S. Approval: 2001","author":"FDA Galantamine Label","year":"2024","unstructured":"FDA Galantamine Label. ZUNVEYL (benzgalantamine) delayed-release tablets, for oral use initial U.S. Approval: 2001 (U.S. Food and Drug Administration (FDA). 2024."},{"key":"e_1_3_8_38_1","volume-title":"EXELON\u00ae PATCH (Rivastigmine Transdermal System) Initial U.S. Approval: 2000","author":"FDA Rivastigmine Label","year":"2024","unstructured":"FDA Rivastigmine Label. EXELON\u00ae PATCH (Rivastigmine Transdermal System) Initial U.S. Approval: 2000 (U.S. Food and Drug Administration (FDA). 2024."},{"key":"e_1_3_8_39_1","volume-title":"ADUHELM\u00ae (aducanumab-avwa) injection, for intravenous use initial U.S. Approval: 2021","author":"FDA Aducanumab Label","year":"2023","unstructured":"FDA Aducanumab Label. ADUHELM\u00ae (aducanumab-avwa) injection, for intravenous use initial U.S. Approval: 2021 (U.S. Food and Drug Administration (FDA). 2023."},{"key":"e_1_3_8_40_1","volume-title":"LEQEMBI\u00ae (lecanemab-irmb) injection, for intravenous use initial U.S. Approval: 2023","author":"FDA Lecanemab Label","year":"2024","unstructured":"FDA Lecanemab Label. LEQEMBI\u00ae (lecanemab-irmb) injection, for intravenous use initial U.S. Approval: 2023 (U.S. Food and Drug Administration (FDA). 2024."},{"key":"e_1_3_8_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/nqaa303"},{"key":"e_1_3_8_42_1","article-title":"Clinical practice guideline for the treatment of depression across three age cohorts","author":"McQuaid JR","unstructured":"McQuaid JR, Lin EH, Barber JP, et al. Clinical practice guideline for the treatment of depression across three age cohorts. Am Psychol Assoc. [cited 2019 Aug.","journal-title":"Am Psychol Assoc"},{"key":"e_1_3_8_43_1","article-title":"Planning policy impact assessments and choosing the right methods: manual for development practitioners","author":"Gro\u00dfmann A","unstructured":"Gro\u00dfmann A, Lehr U, Lutz C, et al. Planning policy impact assessments and choosing the right methods: manual for development practitioners. GIZ, Eschborn. Published online 2016. https:\/\/www.gws-os.com\/en\/publications\/all-publications\/detail\/2016-planning-policy-impact-assessments-and-choosing-the-right-methods-manual-for-development-practitioners","journal-title":"GIZ, Eschborn"},{"key":"e_1_3_8_44_1","unstructured":"The FDA an agency within the USD of H and HS. FDA converts novel Alzheimer\u2019s disease treatment to traditional approval."},{"volume-title":"FDA converts lecanemab to traditional approval","author":"Alzheimer\u2019s Disease International","key":"e_1_3_8_45_1","unstructured":"Alzheimer\u2019s Disease International. FDA converts lecanemab to traditional approval https:\/\/www.alzint.org\/news-events\/news\/fda-converts-lecanemab-to-traditional-approval\/."},{"key":"e_1_3_8_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-021-01125-y"},{"key":"e_1_3_8_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32205-4"},{"key":"e_1_3_8_48_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2018-0009"},{"key":"e_1_3_8_49_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207505"},{"key":"e_1_3_8_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pbj.0000000000000236"},{"key":"e_1_3_8_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadm.2018.12.003"},{"key":"e_1_3_8_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/jme-2022-108475"},{"key":"e_1_3_8_53_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2018-0009"},{"key":"e_1_3_8_54_1","unstructured":"Lin GA Whittington MD Synnott PG et al. Aducanumab for Alzheimer\u2019s disease: effectiveness and Value; draft evidence report. 2021 [cited 2025 Jan 22]. Available from: https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_ALZ_Final_Report_080521.pdf"},{"key":"e_1_3_8_55_1","unstructured":"Eli Lilly and Company. Donanemab follow-on study: safety Tolerability and efficacy in symptomatic Alzheimer\u2019s disease with validation of remote neuropsychological assessments. 2024."}],"container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2025.2507427","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T11:45:52Z","timestamp":1764589552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737167.2025.2507427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,11,26]]}},"alternative-id":["10.1080\/14737167.2025.2507427"],"URL":"https:\/\/doi.org\/10.1080\/14737167.2025.2507427","relation":{},"ISSN":["1473-7167","1744-8379"],"issn-type":[{"type":"print","value":"1473-7167"},{"type":"electronic","value":"1744-8379"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-03-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}